We report outcomes in advanced lymphoma patients (n ¼ 32) who enrolled in a trial of prospectively planned combined autologous/reduced-intensity transplantation (RIT) (n ¼ 25) or who received RIT shortly after prior autografting because of high relapse risk or progressive disease (n ¼ 7). Nine patients on the autologous/RIT transplant protocol did not proceed to planned RIT because of patient choice (n ¼ 4), disease progression (n ¼ 3), toxicity (n ¼ 1), or no adequate donor (n ¼ 1). Among the 23 other patients, RIT was started a median of 59 days (range 31-123) after autologous transplant. Fifteen patients had related donors, five patients had unrelated donors, and three patients had cord blood donors. Among all patients completing RIT, the median overall survival time was 385 days (95% CI 272-792), and the median relapse-free survival time was 157 days (95% CI 119-385). At the time of reporting, six patients (26%) remain alive and three patients (13%) remain alive without relapse. The 100-day transplant-related mortality (TRM) was 9% among all patients and was 0% among matched sibling donors. Overall TRM was 43%. Tandem transplant is feasible in advanced lymphoma with low early TRM. However, practical challenges associated with the strategy were significant and high levels of late TRM due to graft-versus-host disease and infections suggest that modifications of the procedure will be needed to improve outcomes and patient retention.
ablative transplant; reduced-intensity transplant While autologous transplantation and conventional allogeneic transplantation each offer potential roles in the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), each modality has its limitations. For both HD and NHL, high-dose therapy followed by autologous stem cell rescue has become the standard of care for relapsed disease. [1] [2] [3] Unfortunately, there has been relatively little improvement in the efficacy of high-dose regimens in the last decade, and relapse following autologous transplant remains the most important cause of treatment failure. Recently, rituximab has shown promise in NHL, but studies using this agent have not matured. [4] [5] [6] Allogeneic transplant has yielded lower relapse rates compared to autologous transplant in both HD and NHL, likely due to an important graft-versus-tumor (GVT) effect. Overall survival rates after allografting, however, may not be improved as compared to autografting because of high mortality risk mediated by combined toxicities of regimens, immunosuppressive agents, and graft-versus-host disease (GVHD). [7] [8] [9] [10] [11] [12] Reduced-intensity transplantation (RIT) is a modification of conventional allografting that aims to exploit GVT effects while reducing conditioning-related toxicity. A variety of RIT regimens have been reported with a broad range of therapeutic intensities. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] For indolent diseases such as chronic phase chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and lowgrade lymphomas, the GVT effect resulting from RIT may be sufficient by itself to contain or cure disease. 14, 19, 21, [23] [24] [25] [26] With more aggressive NHL and HD, GVT responses may be insufficient when tumors are bulky and tumor growth is rapid. In these circumstances, intensive cytoreduction prior to allografting may allow GVT reactions to be exploited. Conceivably, tandem autologous transplant and RIT might improve outcomes over either approach used alone and over conventional allografting. Autologous transplant can be used to achieve significant cytoreduction, usually with rapid resolution of toxicity, and a subsequent RIT allograft may produce an additional clinically important GVT response and eradicate residual disease. The toxicities of this combined approach might be less severe than those associated with traditional myeloablative allogeneic transplants, where allografting mortalities in the largest series reported to date ranged from 33% in highgrade NHL to 51.7% in HD. 12 There is scant data currently available concerning this tandem transplant strategy. In two reported studies in which very low-intensity RIT conditioning regimens were utilized, one of multiple myeloma 27 using low-dose TBI and one of HD and NHL 28 using fludarabine and cyclophosphamide, prospectively planned RIT using matched sibling donors was well tolerated shortly after autologous transplant with low early transplant-related mortality (TRM). In a recent pilot study, high-dose BEAM chemotherapy given without stem cell support and followed 28 days later by RIT was demonstrated to be feasible with acceptable toxicity, but still with substantial GVHD. 29 In several other series, RIT using various protocols has been performed successfully at longer intervals after autografting as salvage therapy in patients with NHL or HD. 21, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] These data support the concept that tandem transplantation is feasible and that GVT effects can be potent against some lymphomas.
To evaluate further the feasibility of a tandem transplant approach for lymphoma, we investigated autografting followed by RIT with different donor types using 200 cGy TBI plus or minus fludarabine preconditioning in patients with HD and aggressive NHL. This RIT approach has previously been demonstrated to be well tolerated and effective in some older patients with a variety of hematological malignancies, but has not been studied in the setting of tandem transplantation for lymphoma. 21 We report on two cohorts of patients, one enrolled on a prospectively planned combined autologous-allogeneic (auto-allo) transplant protocol and a second cohort that underwent consolidation or salvage RIT at a similar time after autologous transplant. The latter patients provide additional data on the feasibility of the tandem transplant approach.
Patients and methods

Patients
From May 21, 1999 to February 17, 2003, 32 patients with NHL or HD were offered treatment protocols at the University of Colorado Hospital in Denver, CO that incorporated planned auto-allo transplant (n ¼ 25) or RIT as consolidation or salvage of high-risk or progressive disease (n ¼ 7). Some patients from the latter group could not be enrolled in the prospective auto-allo protocol because of insurance denial or their wish to evaluate outcome from autografting prior to proceeding to allografting. All patients were either in relapse or considered high-risk for relapse after autografting at the time of enrollment. Patients were defined as high-risk on the basis of several criteria including failure of second-line chemotherapy to produce remission, early disease progression following treatment, or histology unlikely to be cured by autografting alone (mantle cell, low-grade lymphoma). Patients and donors signed written informed consents on protocols approved by the institutional review board.
Characteristics of these patients are summarized in Tables  1 and 2 .
Entry criteria included SWOG 0-1 performance status; age 418 years; absolute neutrophil count (ANC) 41000/ mm 3 , platelets 450 000/mm 3 , hemoglobin 410 g/dl; left ventricular ejection fraction 445% by MUGA; creatinine clearance 460 mg/ml; DLCO 460% of predicted; and SGOT/SGPT/bilirubin o twice normal. The use of related or unrelated donors (including cord blood) was permitted for RIT. Among unrelated donors the use of fully matched unrelated donors was prioritized over the use of cord blood. Study data were collected through November 2003.
Autologous HCT
Autologous peripheral blood progenitor cells (PBSCs) were collected by apheresis after mobilization with granulocytecolony-stimulating factor (G-CSF) or chemotherapy plus G-CSF and unmanipulated products were cryopreserved using standard techniques. A minimum of 2 Â 10 6 /kg CD34 þ cells was required for autologous transplant. For the first seven patients on the auto-allo protocol, the preparative regimen was busulfan and cyclophosphamide (BU/CY) (busulfan 1 mg/kg orally every 6 h on days À7, À6, À5, À4 and cyclophosphamide 60 mg/kg IV on days À3, À2). All other patients were prepared for autologous transplant with BEAM (BCNU 300 mg/m 2 IV on day -7, etoposide 200 mg/m 2 IV on days -6 through -3, cytarabine 200 mg/m 2 bid IV on days -6 through -3, and melphalan 140 mg/m 2 IV on day -2). Autologous PBSCs were thawed and infused on day 0. Patients received standard prophylaxis against pneumocystis carinii (PCP), fungal infections, herpes simplex, and varicella-zoster virus (VZV) reactivation. Prophylactic broad-spectrum antibiotics were administered during neutropenia (ANCo500).
Reduced-intensity allogeneic transplants
Donor matching was performed at HLA-A, B, and C (serotyping for related donors, molecular typing for unrelated donors) and at HLA-DRB1 and DBQ1. For cord blood transplants matching was performed by serology at HLA-A, B, and DRB1 with a requirement for a 4/6 or greater match. For patients receiving an HLAmatched-related transplant, donors received daily filgrastim at a dose of 10 or 16 mg/kg with leukapheresis performed on days 4 and 5 of filgrastim. A minimum of 3 Â 10 6 /kg CD34 þ cells were collected and infused. Unrelated donor PBSCs were obtained through the National Marrow Donor Program. Cord blood units were purchased from established cord blood banks.
Upon recovery from autografting, as defined by resolution of mucositis due to the autologous transplant and recovery to an ANC 42000/mm 3 , patients on the auto-allo protocol were expected to undergo RIT within 3 months after their autologous transplant. Remission status after autografting was not used to determine eligibility for allografting.
The preparative regimen for RIT was TBI 200 cGy on day 0 for related donor transplants with additional fludarabine 30 mg/m 2 Â 3 on days À4 through À2 for unrelated donor and cord blood transplants. RIT was performed in an outpatient setting with patients admitted as needed for management of complications. Postgrafting immunosuppression included mycophenolate mofetil (MMF) 15 mg/kg twice daily orally from the evening of day 0 until day þ 28 combined with either cyclosporine or tacrolimus. All patients on the auto-allo protocol and cord blood recipients received cyclosporine and MMF. Other patients were enrolled onto RIT protocols that used tacrolimus and MMF. Patients receiving cyclosporine were treated with initial doses of 4 mg/kg twice daily orally from day À3. Cyclosporine doses were adjusted to target a level of 350-400 ng/dl. Patients receiving tacrolimus were treated with 0.03 mg/kg twice daily orally to target levels of 10-20 ng/ml. These agents had taper schedules that were initiated 2 or 3 months posttransplant and were scheduled to be completed at six months post transplant. If disease progression occurred and no GVHD was present, immunosuppression was tapered and discontinued over several weeks.
Analyses of chimerism and residual disease
Donor chimerism was assessed using fluorescent in situ hybridization (FISH) to detect X and Y chromosomes in the case of sex-mismatched donor-recipient pairs or polymerase chain reaction (PCR) to detect polymorphic microsatellite regions in sex-matched pairs. Complete response (CR) was defined as complete disappearance of all detectable tumor for a minimum of 4 weeks. Partial response (PR) was defined as a 50% or greater decrease in the sum of the products of all diameters of measurable lesions for a minimum of four weeks as well as no simultaneous increase in the size of any lesion or appearance of any new lesion. Stable disease (SD) was defined as no change or a response less than a partial response for a minimum of 4 weeks without the appearance of new lesions or worsening symptoms. Progressive disease (PD) was defined as an unequivocal increase in the size of any measurable disease. Relapse was defined as the appearance of any new disease or the reappearance of disease after the patient had achieved CR.
Statistical methods
Overall survival and relapse-free survival were estimated by the Kaplan-Meier method. The incidence of GVHD was summarized using cumulative incidence estimates. 48 The statistical analyses were carried out using software Number Cruncher Statistical System (NCSS 2001, Kaysville, UT, USA) and SAS v8.2 (SAS institute, NC, USA).
Results
Five patients with HD had a median age of 32. 5 years (range 23-56). Twenty-seven patients with NHL had a median age of 52 years (range 29-66). Among NHL patients disease subtypes were: diffuse large B cell (n ¼ 6), transformed follicular cell lymphoma (n ¼ 5), mantle cell lymphoma (n ¼ 5), CLL or small lymphocytic lymphoma with Richter's transformation to diffuse large B-cell lymphoma (n ¼ 3), follicular cell lymphoma (n ¼ 4), anaplastic large cell (n ¼ 2), and T-cell lymphoma not otherwise specified (n ¼ 2).
At the time of autografting the median number of prior chemotherapy regimens was 3 (range 1-7). Three patients had CR to their most recent treatment, eight had PR, nine had SD, and 12 had PD.
Autografting
Among the 32 patients in this study, autografting was generally well tolerated. One patient (3%) died of a complication related to autografting. Excluding one patient without platelet recovery prior to RIT, the median duration of neutrophils o500/ml and platelets o20,000/ml were 9 days (range 5-18) and 12 days (range 4-40), respectively. Two patients developed severe veno-occlusive disease (VOD) after receiving BU/CY. This led to a change in autologous transplant regimen to BEAM. Three patients had pulmonary toxicity after BEAM, two of whom responded immediately to oral steroids and completed RIT as planned. The third patient developed severe pulmonary toxicity requiring high-dose intravenous steroids. She also developed encephalopathy and rapidly progressive disease and was taken off protocol.
Three patients in CR at the time of autografting remained in CR. Six additional patients achieved CR following autografting. Three patients had PR, 10 patients had SD, and nine patients had PD following autografting. One patient died unexpectedly during manipulation of his central catheter with clinical suspicion of air embolus 28 days after autografting. Among the patients with PD, early disease progression was treated with rituximab in two cases and with radiation in one case prior to RIT.
RIT
Among the 32 patients, 25 were enrolled on the prospective auto-allo protocol and seven underwent consolidation or salvage RIT at a similar time after autologous transplant without being prospectively enrolled on the auto-allo protocol. Of the 25 patients enrolled in the prospective auto-allo protocol, nine patients (36%) did not undergo RIT using low-dose TBI for the following reasons: Four patients achieved CR after autografting and declined RIT. One of these patients developed progressive marrow failure and died of aplasia after an unrelated donor RIT performed 370 days following autografting. One patient with transformed CLL died unexpectedly of a presumed air embolus during manipulation of a central catheter prior to scheduled RIT. One patient developed rapidly progressive HD and VOD following autografting and chose not to pursue RIT. For one patient with follicular cell lymphoma, a suitable donor could not be found. Two of the planned auto-allo patients (with follicular cell and mantle cell lymphoma, respectively) had rapidly progressive disease following autografting and were taken off protocol. They received allogeneic transplants after more intensive preparative regimens, and both died shortly after allogeneic transplant.
Among the 23 patients who completed RIT with the planned low-dose TBI-based regimen (16 of them prospectively enrolled on the auto-allo protocol and seven (n ¼ 15) as salvage or consolidation therapy), related donors were HLA-identical (n ¼ 14) or mismatched at one HLA locus (n ¼ 1). Volunteer unrelated donors (n ¼ 5) were HLAidentical (n ¼ 4) or mismatched at one HLA locus (n ¼ 1). Cord blood donors (n ¼ 3) were HLA-identical (n ¼ 2) or mismatched at two HLA loci (n ¼ 1). In all, 11 patients had sex-mismatched donors and 12 had sex-matched donors. Two patients received allografts with bone marrow, 18 patients received G-CSF mobilized PBPCs, and three patients received cord blood.
RIT was started a median of 59 days (range 31-123) after autologous transplant. Among patients on the prospective auto-allo protocol, RIT was started a median of 52 days (range 31-123) after autologous transplant. Among the seven patients receiving RIT as salvage or consolidation therapy, RIT was started a median of 66 days (range 34-78) after autologous transplant. Results of these 23 patients are summarized in Tables 3 and 4 .
Engraftment and chimerism
All recipients of G-CSF mobilized PBPCs had sustained donor cell engraftment. Two patients who received bone marrow grafts experienced graft rejection. The first one, who had mantle cell lymphoma, was transplanted from a 5/6 matched sibling donor. A successful second RIT was performed 125 days later using a fully matched unrelated donor PBPC graft with a conditioning regimen including antithymocyte globulin, fludarabine, and total lymphoid irradiation. The patient is alive in CR at 1614 days post transplant. The second patient developed graft failure following transplant from an HLA-identical sibling donor who had rheumatoid arthritis. Bone marrow was used to avoid exposing the donor to G-CSF, which may cause flares in rheumatoid arthritis. 49, 50 Two of three patients to receive cord blood (one matched and one 4/6 mismatched) engrafted by day 100. The third cord blood recipient (matched) failed to engraft platelets following autografting and never engrafted after RIT. Among the remaining 20 patients, the median days of neutrophilso500/ml and platelets o20,000 ml were 3 (range 0-21) and 0 (range 0-26), respectively. Of the 20 patients who engrafted (including two cord blood donors, 12 sibling matched donors, and five unrelated donors) 19 achieved greater than 95% chimerism (either peripheral blood CD3 cells or bone marrow) at one or more time points before day 100. No chimerism data was available for one patient who had very early disease progression and died of PD 78 days following RIT from a matched sibling donor. Only four patients were given donor lymphocyte infusions (DLI), in each case in an attempt to control PD rather than to increase chimerism.
Toxicity
In all, 14 patients had 24 major infectious episodes at some point after RIT, eight of which were fatal. These included: six aspergillus infections, two nocardia infections, one west nile virus infection, one fungal sinusitis with mucor, one fungal infection not otherwise specified, six major bacterial infections, one CMV pneumonitis, three CMV enteritis, one herpes pneumonia, and two other viral infections. One patient developed thrombocytopenic thrombotic purpura (TTP) after RIT. Two patients died of transplant complications within 100 days of RIT (100 day TRM ¼ 9%). One patient who died 43 days after matched cord blood RIT had never recovered platelet counts following autografting, had PD, and had poor performance status at the time of cord blood RIT. Another patient died of infection after developing grade 3 aGVHD 96 days after matched unrelated RIT.
Overall, 10 patients died of causes related, at least in part, to their transplant (TRM ¼ 43%). Two of these patients had relapsed disease at some point prior to their death. Causes of death included: infection/GVHD (n ¼ 5), infection (n ¼ 2), chemotherapy toxicity/graft failure/disease progression (n ¼ 1), infection/graft failure (n ¼ 1), and suicide in the setting of induced extensive chronic GVHD (this patient had relapsed diseased that was stabilized by immunosuppression taper) (n ¼ 1). Four of 14 patients (29%) who received matched sibling donors experienced TRM and six of nine patients (67%) who received unrelated or cord blood donors experienced TRM.
Graft-versus-host disease
In all, 12 patients developed acute GVHD (aGVHD). Among patients receiving transplants from matched sibling donors, the incidence of grade II-IV aGVHD was 0.36 (95% CI 0.18-0.72) and the incidence of grade III-IV aGVHD was 0.07 (95% CI 0.01-0.47). Among patients receiving transplants from unrelated donors, the incidences of grades II-IV and III-IV aGVHD were both 0.22 (95% CI 0.07-0.75).
In all, 15 patients developed chronic GVHD (cGVHD). In five of these patients, cGVHD developed after immunosuppression was tapered early because of progressive disease. Among matched sibling donors, the incidence of cGVHD was 0.69 (95% CI 0.47-0.99). Among unrelated donors, the incidence of cGVHD was 0.61 (95% CI 0.34-1.00).
Disease response
Of the 23 patients to complete the tandem transplant (including the seven patients who underwent RIT as salvage or consolidation therapy), five were in CR prior to RIT (post autografting), three were in PR, 10 had SD, and five had PD. All five patients in CR remained in CR after RIT. One patient in PR developed CR, while two patients in PR developed PD following RIT. Among the 10 patients with SD, five ultimately developed CR following RIT, one developed PR, and four developed PD. Three patients with PD developed further PD, and two with PD developed SD. A total of 11 patients had relapses at some point after RIT. Following immunosuppression taper after relapse, two patients developed CR and one patient developed SD. DLIs were utilized in the four PD patients who did not have evidence of GVHD off immunosuppression. No patients responded to DLI.
Survival
Among the 23 patients to complete tandem transplant (including the seven patients who underwent RIT as salvage or consolidation therapy) the median overall survival time from time of RIT was 385 days (95% CI 272-792), and the median relapse-free survival time from time of RIT was 157 days (95% CI 119-385) (Figures 1 and  2 ). Six (26%) remain alive at the time of reporting (four in CR and two with PD). Six died of PD. Among the nine additional patients who died of causes other than PD, six died in CR, one died with PR, and two died with SD. Causes of death and disease status at time of death for each patient are summarized in Table 4 . One patient was alive in CR when lost to follow up at 370 days post RIT, and one was alive with PD when lost to follow up 923 post RIT.
Among the nine patients on the auto-allo protocol who did not complete planned RIT, three remain alive at the time of reporting (two in CR and one with PD).
Discussion
Early transplant mortality has been the major limitation of applying allogeneic transplants for lymphoma. Nonetheless, interest in allografting remains strong because of demonstrated graft-versus-lymphoma (GVL) effects and successful treatment by allografting of some autografting failures. How best to capture these GVL effects remains under investigation. Here, we examined the feasibility of performing autologous transplant followed shortly by RIT with a very lowintensity conditioning regimen among patients with aggressive NHL and HD. By separating the high-dose regimen from the allografting procedure, it is possible to avoid superimposing aGVHD on regimen-related toxicities. We also sought to determine the feasibility of prospectively planning tandem transplants and using different donor types. Our results provide further evidence that the tandem transplant strategy can be applied in HD and NHL with a low 100-day TRM.
The principal purpose of our study was to examine the early mortality rates of tandem transplantation. Early outcomes of autologous transplant in our study were comparable to outcomes in previous trials of autologous transplantations. Despite a short interval of 2 months to RIT, allografting was well tolerated with this conditioning regimen. Early toxicity from RIT compared favorably to that of traditional allogeneic transplant. Overall 100-day TRM was only 9% and none of 14 matched sibling donor patients experienced TRM within this period.
Nearly all patients were able to achieve high-level chimerism without DLI. Two graft rejections occurred. In one case bone marrow from a donor with rheumatoid arthritis was used to avoid exposing the donor to G-CSF. In the other case, the first patient treated, bone marrow from a mismatched donor was chosen to try to avoid cGVHD risk. Subsequent data from unrelated donor transplants has shown bone marrow to be inferior to PBPCs for transplants after fludarabine-TBI with a higher risk of graft failure. 51 Among three cord blood transplants, two engrafted and had measurable anti-tumor responses, including one CR associated with GVHD. A third patient died at 43 days after RIT without clear signs of engraftment. The ability to engraft the two cord blood units after fludarabine-TBI may have been facilitated by the combined immunosuppressive effects of prior therapy including the recent autografts.
Despite the favorable early safety profile there was a high rate of late complications, principally infection and cGVHD. Similar observations were made in tandem auto-allo transplants for myeloma, where early toxicity was eliminated but late GVHD was the main problem. 27 Whether the late mortality can be reduced by modified immunosuppression strategy remains to be determined. Although the incidence of cGVHD was relatively high, five of the 15 patients who developed it did so in the setting of accelerated immunosuppression tapers to control PD. The incidence of cGVHD was similar to that seen with conventional allografts using PBPCs.
A second goal of our study was to examine the feasibility of prospectively planning auto-allo transplants. Our results demonstrate some important differences from the two previous auto-allo studies and raise important questions about challenges associated with tandem transplant for lymphoma. Nine (36%) of 25 patients on our auto-allo protocol did not complete the scheduled RIT. In contrast, in a previous study of auto-allo transplant for multiple myeloma, 52 (96%) of 54 patients completed planned autoallo transplants. 27 This discrepancy underscores potential differences between auto-allo transplant for multiple myeloma as compared to NHL and HD. The low toxicity of autografting for multiple myeloma, the slower progression of the disease after autografting, and the fact that myeloma is largely incurable by autografting all likely contributed to the high rate of completing tandem transplant. In contrast, auto-allo transplant for NHL and HD presents several difficulties. First, relapse of aggressive lymphoma frequently occurs within several months of autologous transplant, suggesting that RIT needs to be employed very early after autografting to capitalize maximally on cytoreduction from high-dose chemotherapy. Given the low toxicity encountered at a median transplant interval of 2 months in this study, it is likely that allografting might be performed sooner after autografting, though this interval is not easily controlled for individual patients due to toxicity encountered in autografting and donor availability, particularly when unrelated donors are used. Second, autografting may cure NHL, and some patients either declined RIT after reaching CR with autografting or elected to wait for adverse autografting outcomes before deciding on proceeding to allografting thus extending the interval between the two procedures. Third, toxicity from the intensive autografting regimens used for NHL may delay or prohibit implementation of RIT. Fourth, if alternative donors are used, they need to be identified and transplants arranged in a narrow time frame.
In a previous auto-allo study of 15 lymphoma patients by Carella et al, 28 outcomes appeared better than in our study; 10 patients remained alive at the time of reporting a median of 337 days after RIT. Patients reported in our study, however, likely had more advanced disease and had a mixture of different donor types. While all patients in the Carella study had responsive disease following autografting (three patients were in CR and 12 patients were in PR), five of 23 patients in our study had PD and eight patients had only SD following autografting. Carella et al appear to have reported only patients who completed both autologous transplant and RIT with good autografting outcomes preceding the RIT. Here we have reported our experience on an intention-to-treat basis from the commencement of autografting. Our results provide support for Carella et al's findings that the tandem auto-allo transplant strategy is technically feasible in lymphoma patients. However, the 36% failure to complete RIT rate indicates that the strategy may not be suitable for some lymphoma patients.
As an additional challenge to implementing prospectively planned tandem transplant in our experience, insurance carriers declined coverage for the tandem transplant procedure for several patients or patients were only authorized to undergo RIT once autograft failure was demonstrated. Some of these patients have been included in the salvage group in our analysis.
Limitations of our paper include the relatively small number of unrelated and cord blood donors as well as the heterogeneous nature of the lymphomas and the small number of patients within lymphoma subgroups. Since each of these factors may impact on outcomes, we have not attempted to draw conclusions about the efficacy of this approach. While the relatively small number of unrelated and cord blood donors in our study limits observations about these patients, it is encouraging that engraftment was achieved with all donor subtypes and GVT effects were seen in each group.
In summary, auto-allo transplant with low-dose TBI for RIT conditioning is feasible in high-risk HD and NHL. However, based on our results, its use in lymphoma will depend on overcoming some significant practical challenges and achieving marked reductions in late TRM. Future objectives should include shortening the interval between autografting and allografting, improving the autografting regimens, finding improved ways of dealing with cGVHD, and evaluating this approach in less advanced lymphomas.
